Hepatitis B virus (HBV)-derived DRB1*0101-restricted CD4 T-cell epitopes help in the development of HBV-specific CD8+ T cells in vivo

Vaccine

Volumn 28, Issue 22, 2010, Pages 3818-3826

  Bayard, Florence ^a,b   Malmassari, Silvina ^a,b   Deng, Qiang ^a,b   Lone, Yu Chun ^c   Michel, Marie Louise ^a,b  

^a INSTITUT PASTEUR   (France)

^b INSERM   (France)

^c HÔPITAL PAUL BROUSSE   (France)

Author keywords

Epitope; T cells; Vaccination

Indexed keywords

EPITOPE; GAMMA INTERFERON; HEPATITIS B VIRUS X PROTEIN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA DR ANTIGEN; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HELPER CELL; HEPATITIS B VIRUS; IMMUNIZATION; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

EID: 77952544349     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.03.026     Document Type: Article

References (38)

1. Dienstag J.L. Hepatitis B virus infection. N Engl J Med 359 October (14) (2008) 1486-1500
2. Chang J.J., and Lewin S.R. Immunopathogenesis of hepatitis B virus infection. Immunol Cell Biol 85 January (1) (2007) 16-23
3. Rehermann B., and Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 5 March (3) (2005) 215-229
4. Guidotti L.G., and Chisari F.V. Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 1 (2006) 23-61
5. Castellino F., and Germain R.N. Cooperation between CD4+ and CD8+ T cells: when, where, and how. Annu Rev Immunol 24 (2006) 519-540
6. Ganem D., and Prince A.M. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 350 March (11) (2004) 1118-1129
7. Malmassari S.L., Deng Q., Fontaine H., Houitte D., Rimlinger F., Thiers V., et al. Impact of hepatitis B virus basic core promoter mutations on T cell response to an immunodominant HBx-derived epitope. Hepatology 45 May (5) (2007) 1199-1209
8. Pajot A., Michel M.L., Mancini-Bourgine M., Ungeheuer M.N., Ojcius D.M., Deng Q., et al. Identification of novel HLA-DR1-restricted epitopes from the hepatitis B virus envelope protein in mice expressing HLA-DR1 and vaccinated human subjects. Microbes Infect 8 October (12-13) (2006) 2783-2790
9. Sponaas A., Carstens C., and Koch N. C-terminal extension of the MHC class II-associated invariant chain by an antigenic sequence triggers activation of naive T cells. Gene Ther 6 November (11) (1999) 1826-1834
10. Freisewinkel I.M., Schenck K., and Koch N. The segment of invariant chain that is critical for association with major histocompatibility complex class II molecules contains the sequence of a peptide eluted from class II polypeptides. Proc Natl Acad Sci USA 90 October (20) (1993) 9703-9706
11. Alexander J., Sidney J., Southwood S., Ruppert J., Oseroff C., Maewal A., et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1 December (9) (1994) 751-761
12. Pajot A., Michel M.L., Fazilleau N., Pancre V., Auriault C., Ojcius D.M., et al. A mouse model of human adaptive immune functions: HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice. Eur J Immunol 34 November (11) (2004) 3060-3069
13. Michel M.L., Davis H.L., Schleef M., Mancini M., Tiollais P., and Whalen R.G. DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans. Proc Natl Acad Sci USA 92 June (12) (1995) 5307-5311
14. Mancini-Bourgine M., Bayard F., Soussan P., Deng Q., Lone Y.C., Kremsdorf D., et al. Hepatitis B virus splice-generated protein induces T-cell responses in HLA-transgenic mice and hepatitis B virus-infected patients. J Virol 81 May (10) (2007) 4963-4972
15. Nayersina R., Fowler P., Guilhot S., Missale G., Cerny A., Schlicht H.J., et al. HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. J Immunol 150 May (10) (1993) 4659-4671
16. Rehermann B., Fowler P., Sidney J., Person J., Redeker A., Brown M., et al. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med 181 March (3) (1995) 1047-1058
17. Loirat D., Lemonnier F.A., and Michel M.L. Multiepitopic HLA-A*0201-restricted immune response against hepatitis B surface antigen after DNA-based immunization. J Immunol 165 October (8) (2000) 4748-4755
18. Betts M.R., Brenchley J.M., Price D.A., De Rosa S.C., Douek D.C., Roederer M., et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 281 October (1-2) (2003) 65-78
19. Ha S.J., West E.E., Araki K., Smith K.A., and Ahmed R. Manipulating both the inhibitory and stimulatory immune system towards the success of therapeutic vaccination against chronic viral infections. Immunol Rev 223 June (2008) 317-333
20. Pajot A., Schnuriger A., Moris A., Rodallec A., Ojcius D.M., Autran B., et al. The Th1 immune response against HIV-1 Gag p24-derived peptides in mice expressing HLA-A02.01 and HLA-DR1. Eur J Immunol 37 September (9) (2007) 2635-2644
21. Kim D., Hoory T., Monie A., Ting J.P., Hung C.F., and Wu T.C. Enhancement of DNA vaccine potency through coadministration of CIITA DNA with DNA vaccines via gene gun. J Immunol 180 May (10) (2008) 7019-7027
22. Kim D., Monie A., He L., Tsai Y.C., Hung C.F., and Wu T.C. Role of IL-2 secreted by PADRE-specific CD4+ T cells in enhancing E7-specific CD8+ T-cell immune responses. Gene Ther 15 May (9) (2008) 677-687
23. Hung C.F., Tsai Y.C., He L., and Wu T.C. DNA vaccines encoding Ii-PADRE generates potent PADRE-specific CD4+ T-cell immune responses and enhances vaccine potency. Mol Ther 15 June (6) (2007) 1211-1219
24. Radcliffe J.N., Roddick J.S., Friedmann P.S., Stevenson F.K., and Thirdborough S.M. Prime-boost with alternating DNA vaccines designed to engage different antigen presentation pathways generates high frequencies of peptide-specific CD8+ T cells. J Immunol 177 November (10) (2006) 6626-6633
25. Shastri N., Cardinaud S., Schwab S.R., Serwold T., and Kunisawa J. All the peptides that fit: the beginning, the middle, and the end of the MHC class I antigen-processing pathway. Immunol Rev 207 October (2005) 31-41
26. Hervas-Stubbs S., Olivier A., Boisgerault F., Thieblemont N., and Leclerc C. TLR3 ligand stimulates fully functional memory CD8+ T cells in the absence of CD4+ T-cell help. Blood 109 June (12) (2007) 5318-5326
27. Assudani D., Cho H.I., DeVito N., Bradley N., and Celis E. In vivo expansion, persistence, and function of peptide vaccine-induced CD8 T cells occur independently of CD4 T cells. Cancer Res 68 December (23) (2008) 9892-9899
28. Higgins D., Marshall J.D., Traquina P., Van Nest G., and Livingston B.D. Immunostimulatory DNA as a vaccine adjuvant. Expert Rev Vaccines 6 October (5) (2007) 747-759
29. Agnellini P., Wiesel M., Schwarz K., Wolint P., Bachmann M.F., and Oxenius A. Kinetic and mechanistic requirements for helping CD8 T cells. J Immunol 180 February (3) (2008) 1517-1525
30. Engelhard V.H., Altrich-Vanlith M., Ostankovitch M., and Zarling A.L. Post-translational modifications of naturally processed MHC-binding epitopes. Curr Opin Immunol 18 February (1) (2006) 92-97
31. Livingston B., Crimi C., Newman M., Higashimoto Y., Appella E., Sidney J., et al. A rational strategy to design multiepitope immunogens based on multiple Th lymphocyte epitopes. J Immunol 168 June (11) (2002) 5499-5506
32. Seder R.A., Darrah P.A., and Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 8 April (4) (2008) 247-258
33. Ishioka G.Y., Fikes J., Hermanson G., Livingston B., Crimi C., Qin M., et al. Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes. J Immunol 162 April (7) (1999) 3915-3925
34. Livingston B.D., Alexander J., Crimi C., Oseroff C., Celis E., Daly K., et al. Altered helper T lymphocyte function associated with chronic hepatitis B virus infection and its role in response to therapeutic vaccination in humans. J Immunol 162 March (5) (1999) 3088-3095
35. Gorse G.J., Baden L.R., Wecker M., Newman M.J., Ferrari G., Weinhold K.J., et al. Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults. Vaccine 26 January (2) (2008) 215-223
36. Bertoletti A., and Gehring A.J. The immune response during hepatitis B virus infection. J Gen Virol 87 June (Pt 6) (2006) 1439-1449
37. Boni C., Fisicaro P., Valdatta C., Amadei B., Di Vincenzo P., Giuberti T., et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 81 April (8) (2007) 4215-4225
38. Milich D.R., Thornton G.B., Neurath A.R., Kent S.B., Michel M.L., Tiollais P., et al. Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen. Science 228 June (4704) (1985) 1195-1199